Last edition
News about "Subcutaneous Petosemtamab"
Merus, Halozyme Partner to Develop Subcutaneous Petosemtamab
Under the agreement, Merus will pay Halozyme upfront and milestone-based payments, with Halozyme also eligible for low- to mid-single-digit royalties on future ENHANZE-enabled petosemtamab sales.
Subcutaneous Petosemtamab | 19/11/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members